Advances in Gold Nanoparticle-Based Combined Cancer Therapy

Date

2020

Authors

Bromma, Kyle
Chithrani, Devika B.

Journal Title

Journal ISSN

Volume Title

Publisher

Nanomaterials

Abstract

According to the global cancer observatory (GLOBOCAN), there are approximately 18 million new cancer cases per year worldwide. Cancer therapies are largely limited to surgery, radiotherapy, and chemotherapy. In radiotherapy and chemotherapy, the maximum tolerated dose is presently being used to treat cancer patients. The integrated development of innovative nanoparticle (NP) based approaches will be a key to address one of the main issues in both radiotherapy and chemotherapy: normal tissue toxicity. Among other inorganic NP systems, gold nanoparticle (GNP) based systems offer the means to further improve chemotherapy through controlled delivery of chemotherapeutics, while local radiotherapy dose can be enhanced by targeting the GNPs to the tumor. There have been over 20 nanotechnology-based therapeutic products approved for clinical use in the past two decades. Hence, the goal of this review is to understand what we have achieved so far and what else we can do to accelerate clinical use of GNP-based therapeutic platforms to minimize normal tissue toxicity while increasing the efficacy of the treatment. Nanomedicine will revolutionize future cancer treatment options and our ultimate goal should be to develop treatments that have minimum side effects, for improving the quality of life of all cancer patients.

Description

Keywords

gold nanoparticles, radiation, chemotherapy, radiosensitizer, drug delivery system, chemoradiotherapy

Citation

Bromma, K., & Chithrani, D. B. (2020). Advances in Gold Nanoparticle-Based Combined Cancer Therapy. Nanomaterials, 10(9), 1-25. https://doi.org/10.3390/nano10091671.